File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intensive chemotherapy for adult lymphoblastic lymphomas

TitleIntensive chemotherapy for adult lymphoblastic lymphomas
Authors
Issue Date1991
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1991, v. 29 n. 1, p. 80-82 How to Cite?
AbstractA total of 20 adult patients presenting with previously untreated lymphoblastic lymphoma underwent an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. If the patients achieved a complete clinical remission (CR) after three courses, they were given intensive consolidation and maintenance chemotherapy based on a protocol that was modified from the L10/L17M regimen of the Memorial Sloan-Kettering group for acute lymphoblastic leukaemia and lymphoblastic lymphoma. Patients exhibiting localised areas of bulky disease were given additional involved-field ratiotherapy. In all, 15 (75%) men and 5 (25%) women were entered in this study. Their median age was 28 years (mean, 30 years; range, 12-64 years). Overall, 3 (15%) had stage II disease, 3 (15%) had stage III disease and 14 (70%) had stage IV disease; 7 (35%) patients exhibited B symptoms and 4 (20%) had bulky disease. The overall (CR) rate was 10/20 (20%), and that following BACOP and m-BACOD therapy was 4/8 (50%) and 6/12 (50%), respectively. In all, 7 of the 10 complete responders (70%) relapsed. The disease-free survival of the ten who achieved a CR was 23% at 3 years. The overall survival of all 20 patients at 3 years was only 37%, and there were very few long-term survivors. More effective treatment for adult lymphoblastic lymphoma is required.
Persistent Identifierhttp://hdl.handle.net/10722/161894
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorChiu, Een_US
dc.contributor.authorLie, Aen_US
dc.contributor.authorHo, FCSen_US
dc.contributor.authorLoke, SLen_US
dc.date.accessioned2012-09-05T05:15:52Z-
dc.date.available2012-09-05T05:15:52Z-
dc.date.issued1991en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1991, v. 29 n. 1, p. 80-82en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161894-
dc.description.abstractA total of 20 adult patients presenting with previously untreated lymphoblastic lymphoma underwent an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. If the patients achieved a complete clinical remission (CR) after three courses, they were given intensive consolidation and maintenance chemotherapy based on a protocol that was modified from the L10/L17M regimen of the Memorial Sloan-Kettering group for acute lymphoblastic leukaemia and lymphoblastic lymphoma. Patients exhibiting localised areas of bulky disease were given additional involved-field ratiotherapy. In all, 15 (75%) men and 5 (25%) women were entered in this study. Their median age was 28 years (mean, 30 years; range, 12-64 years). Overall, 3 (15%) had stage II disease, 3 (15%) had stage III disease and 14 (70%) had stage IV disease; 7 (35%) patients exhibited B symptoms and 4 (20%) had bulky disease. The overall (CR) rate was 10/20 (20%), and that following BACOP and m-BACOD therapy was 4/8 (50%) and 6/12 (50%), respectively. In all, 7 of the 10 complete responders (70%) relapsed. The disease-free survival of the ten who achieved a CR was 23% at 3 years. The overall survival of all 20 patients at 3 years was only 37%, and there were very few long-term survivors. More effective treatment for adult lymphoblastic lymphoma is required.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshCyclophosphamide - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDexamethasone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDoxorubicin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLeucovorin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshMaleen_US
dc.subject.meshMethotrexate - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma - Drug Therapy - Mortalityen_US
dc.subject.meshPrednisone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshVincristine - Administration & Dosage - Adverse Effectsen_US
dc.titleIntensive chemotherapy for adult lymphoblastic lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF00686341-
dc.identifier.pmid1720710-
dc.identifier.scopuseid_2-s2.0-0026006104en_US
dc.identifier.volume29en_US
dc.identifier.issue1en_US
dc.identifier.spage80en_US
dc.identifier.epage82en_US
dc.identifier.isiWOS:A1991GQ47000015-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChiu, E=24827833600en_US
dc.identifier.scopusauthoridLie, A=24284842400en_US
dc.identifier.scopusauthoridHo, FCS=7103408147en_US
dc.identifier.scopusauthoridLoke, SL=7006559512en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats